Inhibitory_effects_of_the_gastrin_receptor_antagonist_(L-365,260)_on_gastrointestinal_tumor_cells._A_selective_gastrin_receptor_(GR)_antagonist,_L-365,260_is_bound_to_the_GR_on_AR42J_cells_with_a_potency_7.5-fold_less_than_G17_(50%_inhibitory_concentration_IC50_G17,_6_x_10(-9)_mol/l;_IC50_L365-260,_4.5_x_10(-8)_mol/l)._G17_is_mitogenic_for_AR42J_cells,_as_assessed_by_75Se-selenomethionine_uptake_and_L-365,260_at_concentrations_of_2.5_x_10(-6)_mol/l_and_2.5_x_10(-7)_mol/l,_(55X_and_5.5_X_the_dose_required_to_displace_50%_125I_G17,_respectively),_and_reduced_optimal_G17_stimulated_mitogenesis_in_75%_of_experiments._The_basal_growth_of_two_human_colon_cancer_cell_lines,_LoVo_and_C146_was_reduced_by_L-365,260_(2.5_x_10(-7)_mol/l)_after_5_days_of_treatment_to_44%_and_64%_of_the_control,_respectively._However,_inhibition_was_followed_by_a_rebound_of_growth_to_control_levels._The_growth_of_AR42J_xenografts_in_nude_mice_was_increased_by_administration_of_G17_(10_micrograms/mouse/d,_P_less_than_0.027)._This_increase_was_blocked_by_coadministration_of_oral_L-365,260_(5_mg/kg/d,_P_less_than_0.034)._L-365,260_could_be_an_important_therapeutic_agent_in_slowing_the_growth_of_GR-positive,_G17-sensitive_gastrointestinal_tumors.